1. Home
  2. JNJ vs NVO Comparison

JNJ vs NVO Comparison

Compare JNJ & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Johnson & Johnson

JNJ

Johnson & Johnson

N/A

Current Price

$286.29

Market Cap

542.4B

Sector

Health Care

ML Signal

N/A

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

N/A

Current Price

$41.51

Market Cap

199.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JNJ
NVO
Founded
1886
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
542.4B
199.4B
IPO Year
2003
2001

Fundamental Metrics

Financial Performance
Metric
JNJ
NVO
Price
$286.29
$41.51
Analyst Decision
Buy
Hold
Analyst Count
23
14
Target Price
★ $279.41
$45.63
AVG Volume (30 Days)
6.9M
★ 8.9M
Earning Date
10-13-2026
11-04-2026
Dividend Yield
1.89%
★ 3.15%
EPS Growth
★ 90.50
N/A
EPS
★ 4.49
N/A
Revenue
N/A
N/A
Revenue This Year
$7.46
$0.06
Revenue Next Year
$6.45
$1.32
P/E Ratio
$63.21
★ $13.60
Revenue Growth
N/A
N/A
52 Week Low
$195.90
$35.12
52 Week High
$286.08
$64.16

Technical Indicators

Market Signals
Indicator
JNJ
NVO
Relative Strength Index (RSI) 66.21 57.17
Support Level $262.26 $41.05
Resistance Level N/A $43.24
Average True Range (ATR) 6.76 0.83
MACD 1.63 0.25
Stochastic Oscillator 93.94 68.09

Price Performance

Historical Comparison
JNJ
NVO

About JNJ Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: